Objective: The mTOR inhibitors have been demonstrated clinical benefits in many cancers(kidney,breast cancer,etc),while the efficacy of mTOR inhibitors in non-small cell lung cancer(NSCLC)remains uncertain.This study takes everolimus as a model to understand the mechanisms accounting for limited response of mTOR inhibitors and to explore the combination approach targeting mTOR inhibitor with the natural compound platycodin D(PD)in NSCLC.